Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutikizumab - AbbVie

Next Previous
Drug Profile

Lutikizumab - AbbVie

Alternative Names: ABT-981

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Bispecific antibodies; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 31 Jul 2018 No development reported - Phase-II for Osteoarthritis in Denmark, Australia, Canada, Canada, France, Italy, Mexico, Netherlands, Spain, Puerto Rico, United Kingdom, Belgium, Belgium, Switzerland, USA (SC)
  • 13 Jun 2018 Clinical pharmacokinetics and pharmacodynamics data from a phase IIa trial in Osteoarthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 03 Nov 2017 Efficacy and adverse events data from a phase IIa trial in Osteoarthritis presented at the the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top